Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 8/20 | 0.43 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.36 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.36 |
| ▸ | F10 | P00742 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14286748 | 0.91 | PTGS1 (0.43) | PTGS1NR1H3PTPN1NR1H2 | |
| SCHEMBL6009746 | 0.91 | PTGS1 (0.43) | PTGS1NR1H3PTPN1NR1H2 | |
| SCHEMBL14286757 | 0.89 | PTGS1 (0.41) | PTGS1NR1H3PTPN1NR1H2CYP19A1 | |
| SCHEMBL12704714 | 0.87 | PTGS1 (0.47) | PTGS1NR1H3PTPN1NR1H2 | |
| SCHEMBL14286758 | 0.87 | PTGS1 (0.47) | PTGS1NR1H3PTPN1NR1H2 | |
| SCHEMBL280447 | 0.87 | PTGS1 (0.41) | PTGS1NR1H3PTPN1NR1H2 | |
| SCHEMBL12704713 | 0.87 | PTGS1 (0.41) | PTGS1NR1H3PTPN1NR1H2 | |
| SCHEMBL12887597 | 0.86 | PTGS1 (0.41) | PTGS1NR1H3PTPN1NR1H2 | |
| SCHEMBL280314 | 0.85 | PTGS1 (0.44) | PTGS1NR1H3PTPN1NR1H2 | |
| SCHEMBL267185 | 0.85 | PTGS1 (0.40) | PTGS1NR1H3PTPN1NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080188475-A1 | Novel Interleukin-1 and Tumor Necrosis Factor-Alpha Modulators, Syntheses of Said Modulators and Their Enantiomers and Methods of Using Said Modulators | NEREUS PHAMACEUTICALS, INC. (US) | 2008-08-07 | — | — | US | disclosed |
| US-20080103328-A1 | Novel Interleukin-1 and Tumor Necrosis Factor-Alpha Modulators, Syntheses of Said Modulators and Their Enantiomers and Methods of Using Said Modulators | NEREUS PHARMACEUTICALS, INC. (US) | 2008-05-01 | — | — | US | disclosed |
| US-20080064753-A1 | Interleukin-1 and tumor necrosis factor-alpha modulators; syntheses of such modulators and methods of using such modulators | HENSLER, MARY | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103328-A1 | Novel Interleukin-1 and Tumor Necrosis Factor-Alpha Modulators, Syntheses of Said Modulators and Their Enantiomers and Methods of Using Said Modulators | TNF, TNFRSF1A, IL1R1 | PTGS1 93/4885NR1H3 466/4885PTPN1 3239/4885 |
| US-20080188475-A1 | Novel Interleukin-1 and Tumor Necrosis Factor-Alpha Modulators, Syntheses of Said Modulators and Their Enantiomers and Methods of Using Said Modulators | IL1A, IL1B, TNF | PTGS1 11/4885NR1H3 1132/4885PTPN1 2311/4885 |
| US-20080064753-A1 | Interleukin-1 and tumor necrosis factor-alpha modulators; syntheses of such modulators and methods of using such modulators | IL1A, IL1B, TNF | PTGS1 20/4885NR1H3 3538/4885PTPN1 2008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.